Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07089381

Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
118 (estimated)
Sponsor
Ain Shams University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis. Objectives : 1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring: * Serum Sirtuin 1(SIRT1) * Serum Myeloperoxidase (MPO) * Serum C-reactive protein (CRP) 2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score). 3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI). 4. To assess any adverse effects related to Resveratrol. Patients: Eligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups: 1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months. 2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTResveratrol 1 gm.59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix, Egypt) (given as one 1000 mg tablets once daily) for 3 months.
DRUGMethotrexate59 patients will receive the standard treatment for management of RA for 3 months

Timeline

Start date
2025-08-01
Primary completion
2026-02-01
Completion
2026-06-01
First posted
2025-07-28
Last updated
2025-07-28

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07089381. Inclusion in this directory is not an endorsement.